Cargando…
Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin that usually results in death from secondary respiratory failure within 2–5 years of diagnosis. Recent studies have identified key roles of cytokine and growth factor pathways in the pathogenesis of IPF. Alt...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204157/ https://www.ncbi.nlm.nih.gov/pubmed/35721111 http://dx.doi.org/10.3389/fphar.2022.918771 |
_version_ | 1784728854440443904 |
---|---|
author | Ma, Hongbo Liu, Shengming Li, Shanrui Xia, Yong |
author_facet | Ma, Hongbo Liu, Shengming Li, Shanrui Xia, Yong |
author_sort | Ma, Hongbo |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin that usually results in death from secondary respiratory failure within 2–5 years of diagnosis. Recent studies have identified key roles of cytokine and growth factor pathways in the pathogenesis of IPF. Although there have been numerous clinical trials of drugs investigating their efficacy in the treatment of IPF, only Pirfenidone and Nintedanib have been approved by the FDA. However, they have some major limitations, such as insufficient efficacy, undesired side effects and poor pharmacokinetic properties. To give more insights into the discovery of potential targets for the treatment of IPF, this review provides an overview of cytokines, growth factors and their signaling pathways in IPF, which have important implications for fully exploiting the therapeutic potential of targeting cytokine and growth factor pathways. Advances in the field of cytokine and growth factor pathways will help slow disease progression, prolong life, and improve the quality of life for IPF patients in the future. |
format | Online Article Text |
id | pubmed-9204157 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92041572022-06-18 Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis Ma, Hongbo Liu, Shengming Li, Shanrui Xia, Yong Front Pharmacol Pharmacology Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease of unknown origin that usually results in death from secondary respiratory failure within 2–5 years of diagnosis. Recent studies have identified key roles of cytokine and growth factor pathways in the pathogenesis of IPF. Although there have been numerous clinical trials of drugs investigating their efficacy in the treatment of IPF, only Pirfenidone and Nintedanib have been approved by the FDA. However, they have some major limitations, such as insufficient efficacy, undesired side effects and poor pharmacokinetic properties. To give more insights into the discovery of potential targets for the treatment of IPF, this review provides an overview of cytokines, growth factors and their signaling pathways in IPF, which have important implications for fully exploiting the therapeutic potential of targeting cytokine and growth factor pathways. Advances in the field of cytokine and growth factor pathways will help slow disease progression, prolong life, and improve the quality of life for IPF patients in the future. Frontiers Media S.A. 2022-06-03 /pmc/articles/PMC9204157/ /pubmed/35721111 http://dx.doi.org/10.3389/fphar.2022.918771 Text en Copyright © 2022 Ma, Liu, Li and Xia. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ma, Hongbo Liu, Shengming Li, Shanrui Xia, Yong Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis |
title | Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis |
title_full | Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis |
title_fullStr | Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis |
title_full_unstemmed | Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis |
title_short | Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis |
title_sort | targeting growth factor and cytokine pathways to treat idiopathic pulmonary fibrosis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204157/ https://www.ncbi.nlm.nih.gov/pubmed/35721111 http://dx.doi.org/10.3389/fphar.2022.918771 |
work_keys_str_mv | AT mahongbo targetinggrowthfactorandcytokinepathwaystotreatidiopathicpulmonaryfibrosis AT liushengming targetinggrowthfactorandcytokinepathwaystotreatidiopathicpulmonaryfibrosis AT lishanrui targetinggrowthfactorandcytokinepathwaystotreatidiopathicpulmonaryfibrosis AT xiayong targetinggrowthfactorandcytokinepathwaystotreatidiopathicpulmonaryfibrosis |